cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer
Creators: name: Zhang, Huahua
name: Zheng, Xiaochun
name: Zhang, Yandong
name: Wang, Jiangfeng
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Medicine
Pharmacology
Biological Sciences not elsewhere classified
Cancer
Science Policy

description: <b>Aim:</b> To evaluate the cost–effectiveness of aumolertinib as the epidermal growth factor receptor-mutated advanced nonsmall-cell lung cancer first-line treatment from the Chinese healthcare system perspective. <b>Methods:</b> A Markov model was developed based on the AENEAS trial. Only direct medical costs were considered in the model. Utilities were obtained from published literature. Sensitivity and scenario analyses were performed to explore the robustness of the model. <b>Results:</b> Compared with gefitinib, aumolertinib yielded an additional 0.941 expected life-years and 0.692 quality-adjusted life-years (QALYs), with an incremental cost of $18,855.55 over a 20-year time horizon. The incremental cost–effectiveness ratios were $20,051.67/life-year and $27,272.29/QALY, that below the willing-to-pay threshold of $38,223.34/QALY. <b>Conclusion:</b> Aumolertinib was a cost-effective alternative first-line treatment for patients with epidermal growth factor receptor-positive advanced nonsmall-cell lung cancer in China. This study assesses the costs and health outcomes associated with aumolertinib therapy for Chinese patients diagnosed with advanced or metastatic nonsmall cell lung cancer (NSCLC). Aumolertinib therapy is a specific type of medication used to treat a certain type of lung cancer called nonsmall cell lung cancer. It is a newer treatment that targets certain genetic changes in the cancer cells. The costs and treatment benefits were estimated using data from the AENEAS trial, provincial medical cost lists and previously published studies. A Markov model was developed to simulate disease progression. Provincial Medical Cost Lists are official lists maintained by different provincial governments in China that specify the drugs and their prices that are covered by the public healthcare system. A Markov Model is a mathematical tool used to predict how a disease might progress over time. It is like a simulation where the possible outcomes of the disease are analyzed, helping to understand the likely course of the disease and how different treatments might affect it. The cost of treatment with aumolertinib for Chinese patients with advanced or metastatic NSCLC was considered to be acceptable based on the benefits it provides. The results suggest that aumolertinib is a cost-effective treatment for patients with advanced or metastatic NSCLC in China. Aumolertinib has demonstrated significant clinical benefit as a first-line treatment for patients with advanced epidermal growth factor receptor-mutated NSCLC. A Markov model was developed to compare the cost–effectiveness of aumolertinib and gefitinib. Clinical data were extracted from the AENEAS trial. Direct medical costs incorporated in the model included costs of epidermal growth factor receptor tyrosine kinase inhibitor treatment, follow-up, hospitalization, adverse event management, subsequent treatment postprogression and end-of-life care. The base-case incremental cost–effectiveness ratios were $20,051.67/life-year and $27,272.29/quality-adjusted life-year. Aumolertinib proved to be a cost-effective first-line treatment option for nonsmall cell lung cancer in China. The price of aumolertinib had the greatest impact on the incremental cost–effectiveness ratio. The probability of aumolertinib being a cost-effective treatment was 96.8% at the willingness-to-pay threshold.